Heartflow, Inc. (HTFL): Results of Operations and Financial Condition
Heartflow, Inc. (HTFL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 htfl-20260813xex99_1.htm EX-99.1 Exhibit 991 20260813 Exhibit 99.1 Heartflow Reports Second Quarter 202 6 Financial Results and Raises Full Year 2026 Guidance SAN FRANCISCO — August 1 3 , 202 6 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology fo
How this was made
The 30-second read
Why it matters
The key tradable update is the raised 2026 revenue range and non-GAAP gross margin target, alongside quarterly gross margin expansion and improved non-GAAP loss profile.
Market read
Traders can update valuation and positioning based on the guidance increase and margin/operating leverage signals from Q2.
What to watch
Investors may discount the guidance raise if case volume growth slows or if Plaque becomes a smaller-than-expected contributor to durable profitability.
Background
The filing is an SEC 8-K with Exhibit 99.1 covering Heartflow’s Q2 2026 results and updated full-year 2026 guidance.
Ticker impact
Heartflow reported Q2 revenue of $64.1M (+48% YoY) and raised 2026 revenue guidance to $246M-$250M.
Near-term bias upward as traders reprice 2026 growth and margin scalability; follow-through depends on whether investors focus on operating loss trajectory.
The filing discloses both quarterly results and an explicit full-year guidance increase, with gross margin rising to 83% and non-GAAP gross margin to 83.3%.
Market effects
Signals continued demand and monetization momentum in AI-enabled cardiovascular diagnostics, potentially supportive for sentiment toward similar med-tech/AI imaging names.
Primarily US-focused revenue growth (U.S. revenue +51% YoY) may reinforce domestic med-tech growth expectations.
International revenue growth was positive (+12% YoY), but the guidance raise is the main global read-through.
Counterpoint
Despite guidance lift, GAAP operating loss widened to $17.9M and operating expenses rose as the company invests in sales, technology, and clinical research.
Key entities
- companyHeartflow, Inc.
AI technology for diagnosing coronary artery disease (CAD), reporting Q2 results and raising 2026 guidance.
- executiveJohn Farquhar
President and CEO, quoted on growth drivers including FFR CT durability and Plaque emergence.
